Pharmaceutical Products of the Future: 50-Company Biopharma and Traditional Pipeline Analysis to 2016

Attention: There is an updated edition available for this report.
 
   Single User - $2,500
   Site License (one location, 10 users) - $3,750
   Corporate License - $5,000



Loading...
Published Aug 3, 2012 | 220 Pages | Pub ID: KLI4859780

What Will the Pharma Industry Look Like in 5 Years?

There are an estimated 724 projects in development from the top 50 pharmaceutical companies.  Together, they have the potential to add billions in value to the current pharmaceutical market in the next five years. What types of drugs are companies developing and what will be the impact of these products on the marketplace and key competitors?   In this report, Kalorama Information has analyzed the late-stage R&D pipeline of the 50 top companies in pharmaceuticals -- the companies that produce the lion's share of industry revenues.

Coverage of the 50 Leading Companies

 This report takes a look at the pipeline of the following companies.  The top companies include pharmaceutical companies that are considered to be the top 50 companies worldwide in terms of generated revenues, these include:

  • Abbott Laboratories
  • Actelion
  • Allergan
  • Amgen
  • Astellas
  • AstraZeneca
  • Baxter International
  • Bayer
  • Biogen IDEC
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Celgene Corp.
  • CSL
  • Daiichi Sankyo
  • Dainippon Sumitomo
  • Eisai
  • Eli Lilly & Co.
  • Forest
  • Gilead Sciences
  • GlaxoSmithKline
  • Grifols SA
  • Hospira
  • Johnson & Johnson
  • Kyowa Kirin
  • Lundbeck
  • Menarini
  • Merck
  • Merck KGaA
  • Mitsubishi Tanabe Pharma
  • Mylan
  • Novartis
  • Novo Nordisk
  • Ono Pharmaceutical Co.
  • Otsuka Pharmaceutical
  • Pfizer
  • Purdue Pharma
  • Reckitt Benckiser
  • Roche
  • Sanofi
  • Santen Pharmaceuticals
  • Servier
  • Shionogi
  • Shire
  • Taisho Pharmacueitcal
  • Takeda
  • TEVA
  • UCB
  • Valeant Pharmaceuticals
  • Warner Chilcott
  • Watson

While the report looks at the entire pipeline to 2015, a key focus of the report is the increasing role of biopharmaceutical products.  The growing interest in biotechnology development has transitioned the pharmaceutical industry to biopharmaceuticals in less than a decade. Companies such as Pfizer, Merck and Novartis have been unable to ignore the benefits of investing in biotechnology and have focused on a pipeline in this direction through strategic acquisitions and partnerships with biotech companies and/or through their own in-house research efforts.

Pipeline Analysis, Key Trends, Market Forecasts

This Kalorama Information market research report captures these trends, extracting sales for all pharmaceutical and biopharmaceutical products (excluding prophylactic vaccines and OTC products) and providing estimates and forecasts of the world biopharma market.

As part of its coverage, the report provides the following:
  • Company Analysis
  • Pipeline Snapshot: Top 20 Companies
  • Market Trends and Value
  • Evaluating Changes in 2011 Market Value
  • The Traditional Pharmaceutical Market
  • Biotechnology Market Facts and Forecast

For the purpose of this study, Kalorama Information has extracted sales for human pharmaceutical and biopharmaceutical products; consumer pharmaceuticals and products; diagnostics; devices; chemicals; agriculture; and animal health. These are areas where many of these companies also compete with significant market shares.

The industry has struggled in recent years but many observers see biopharmaceutical as the key to continued success for market leaders.  Biopharmaceuticals are defined as any substance produced by natural organisms or recombinant techniques consisting of proteins and other products derived from living organisms for the treatment or management of diseases or injuries. Biopharmaceuticals are created through fermentation, recombinant DNA technology, and other bioprocesses. The complex nature of biopharmaceuticals and the growing interest in development of these products has resulted in a flood of new issues affecting the already complicated healthcare market. There are a number of issues and trends which are experienced by the healthcare industry as a whole and others which are unique to biopharmaceuticals, their development and commercialization. 

Issues and Trends discussed in this report include:

  • Biotechnology Drug Development
  • Orphan Drugs
  • Fast Track Drug Status
  • Other Accelerated Methods for Drug Approval
  • Pharmaceutical Regulatory Exclusivity
  • Biosimilar Development
  • Aging Populations
  • Mergers, Acquisitions, and Collaborations
  • Contributors to R&D Success
  • R&D Spending Trends
  • The Role of Contract Research Organizations
  • Sustainability in a Changing Pharmaceutical Industry

In this report,  {{key}} appears {{searchResults.reportMatchCounts[value]}} times